Current Diabetes Reports最新文献_第9页

Thinking Ahead to the Next Generation of Cardiometabolic Investigators: What It Takes to Successfully Engage Underrepresented Minorities in Biomedical and Public Health Careers. 提前思考下一代心脏代谢研究人员:成功参与生物医学和公共卫生事业中代表性不足的少数群体需要什么。

IF 4.2 2区医学

Current Diabetes Reports Pub Date : 2022-07-01 DOI: 10.1007/s11892-022-01472-1

Wendy B White, Kisa K Harris, Amel Mohamed, Frances C Henderson

引用次数: 0

Friend or Foe: a Narrative Review of the Impact of Diabetes Technology on Sleep. 朋友还是敌人:糖尿病技术对睡眠影响的叙述性回顾。

IF 4.2 2区医学

Current Diabetes Reports Pub Date : 2022-07-01 DOI: 10.1007/s11892-022-01468-x

Erin C Cobry, Angela J Karami, Lisa J Meltzer

{"title":"Friend or Foe: a Narrative Review of the Impact of Diabetes Technology on Sleep.","authors":"Erin C Cobry, Angela J Karami, Lisa J Meltzer","doi":"10.1007/s11892-022-01468-x","DOIUrl":"https://doi.org/10.1007/s11892-022-01468-x","url":null,"abstract":"Purpose of review: The purpose of this review is to present a review of sleep science, the relationship between sleep and type 1 diabetes, and highlight the current literature on sleep outcomes in adult and pediatric diabetes technology research.Recent findings: Sleep quality is associated with glycemic outcomes, diabetes self-management, and mental health in people with type 1 diabetes. Diabetes technologies, including insulin pumps, continuous glucose monitors, and hybrid closed-loop systems improve glycemic outcomes. However, many people find this technology challenging for a variety of reasons, including increased burden and frequent alarms, especially during the night. The impact of different devices on sleep quality and quantity has been mixed. The newest technology, the hybrid closed-loop systems, offers the best opportunity for nocturnal glycemic regulation and has improved patient and family perspectives on sleep quality. However, objective sleep assessment has not shown significant improvement on sleep duration. Sleep quality and quantity in people with type 1 diabetes are widely recognized as an important component of health care, and the literature regarding the impact of diabetes devices on sleep is increasing. However, sleep disruptions are common and a barrier to device use. Despite finding minimal changes to sleep duration with device use, subjective accounts of sleep quality are overall positive, especially in those using hybrid closed-loop systems. Sleep quantity and quality are important outcomes to consider as diabetes technology continues to evolve.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"22 7","pages":"283-290"},"PeriodicalIF":4.2,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9996025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

The Use of Diabetes Technology to Address Inequity in Health Outcomes: Limitations and Opportunities. 利用糖尿病技术解决健康结果不平等问题：局限与机遇。

IF 5.2 2区医学

Current Diabetes Reports Pub Date : 2022-07-01 Epub Date: 2022-06-01 DOI: 10.1007/s11892-022-01470-3

Shivani Agarwal, Iman Simmonds, Alyson K Myers

{"title":"The Use of Diabetes Technology to Address Inequity in Health Outcomes: Limitations and Opportunities.","authors":"Shivani Agarwal, Iman Simmonds, Alyson K Myers","doi":"10.1007/s11892-022-01470-3","DOIUrl":"10.1007/s11892-022-01470-3","url":null,"abstract":"Purpose of review: The management of diabetes has been revolutionized by the introduction of novel technological treatments and modalities of care, such as continuous glucose monitoring, insulin pump therapy, and telehealth. While these technologies have demonstrated improvement in health outcomes, it remains unclear whether they have reduced inequities from racial/ethnic minority or socioeconomic status. We review the current literature to discuss evidence of benefit, current limitations, and future opportunities of diabetes technologies.Findings: While there is ample evidence of the health and psychological benefit of diabetes technologies in large populations of people with type 1 and type 2 diabetes, there remain wide disparities in the use of diabetes technologies, which may be perpetuating or widening inequities. Multilevel barriers include inequitable prescribing practices, lack of support for social determinants of health, mismatch of patient preferences and care models, and cost. We provide a review of disparities in diabetes technology use, possible root causes of continued inequity in outcomes, and insight into ways to overcome remaining gaps.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"22 7","pages":"275-281"},"PeriodicalIF":5.2,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9552604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and Efficacy of Inpatient Diabetes Management with Non-insulin Agents: an Overview of International Practices. 非胰岛素药物治疗住院糖尿病患者的安全性和有效性:国际实践综述。

IF 4.2 2区医学

Current Diabetes Reports Pub Date : 2022-06-01 DOI: 10.1007/s11892-022-01464-1

Rodolfo J Galindo, Ketan Dhatariya, Fernando Gomez-Peralta, Guillermo E Umpierrez

引用次数: 7

SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis SGLT2在1型糖尿病合并糖尿病肾病中的抑制作用：潜在的心肾益处可能超过糖尿病酮症酸中毒的可预防风险

IF 4.2 2区医学

Current Diabetes Reports Pub Date : 2022-05-28 DOI: 10.1007/s11892-022-01471-2

Hongyan Liu, V. Sridhar, B. Perkins, J. Rosenstock, D. Cherney

引用次数: 3

The Clash of Two Epidemics: the Relationship Between Opioids and Glucose Metabolism 两种流行病的冲突：阿片类药物与葡萄糖代谢的关系

IF 4.2 2区医学

Current Diabetes Reports Pub Date : 2022-05-20 DOI: 10.1007/s11892-022-01473-0

L. Koekkoek, L. L. van der Gun, M. Serlie, S. L. la Fleur

引用次数: 4

Implementation of Cardiometabolic Centers and Training Programs. 心脏代谢中心和训练计划的实施。

IF 4.2 2区医学

Current Diabetes Reports Pub Date : 2022-05-01 DOI: 10.1007/s11892-022-01459-y

Mohamad B Taha, Neha Rao, Muthiah Vaduganathan, Miguel Cainzos-Achirica, Khurram Nasir, Kershaw V Patel

{"title":"Implementation of Cardiometabolic Centers and Training Programs.","authors":"Mohamad B Taha, Neha Rao, Muthiah Vaduganathan, Miguel Cainzos-Achirica, Khurram Nasir, Kershaw V Patel","doi":"10.1007/s11892-022-01459-y","DOIUrl":"https://doi.org/10.1007/s11892-022-01459-y","url":null,"abstract":"Purpose of review: Type 2 diabetes is frequently accompanied by obesity, nonalcoholic fatty liver disease, chronic kidney disease, and cardiovascular disease, which collectively contribute to the high burden of cardiometabolic disease. This review discusses cardiometabolic disease management, strategies to implement cardiometabolic centers to deliver care, and dedicated programs to train the next generation of cardiometabolic experts.Recent findings: Sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineralocorticoid receptor antagonist have demonstrated beneficial effects across cardiometabolic conditions. However, utilization of effective pharmacotherapies is low in clinical practice, in part due to clinical inertia and traditional sharp delineation in clinical responsibilities of specialists. Multidisciplinary clinics and population-health models can provide comprehensive care but require investment in physical and information technology infrastructure as well as in training and accreditation. Post-internal medicine residency cardiometabolic health training programs have been proposed. Implementing cardiometabolic centers in health systems involves reshaping current practices. Training programs focused on cardiometabolic health are needed to address the growing burden of disease and specific training needs in this ever-expanding area.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"22 5","pages":"203-212"},"PeriodicalIF":4.2,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9337855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetics of Type 2 Diabetes: Implications from Large-Scale Studies. 2型糖尿病的遗传学:来自大规模研究的启示

IF 4.2 2区医学

Current Diabetes Reports Pub Date : 2022-05-01 Epub Date: 2022-03-19 DOI: 10.1007/s11892-022-01462-3

Natalie DeForest, Amit R Majithia

{"title":"Genetics of Type 2 Diabetes: Implications from Large-Scale Studies.","authors":"Natalie DeForest, Amit R Majithia","doi":"10.1007/s11892-022-01462-3","DOIUrl":"10.1007/s11892-022-01462-3","url":null,"abstract":"Purpose of review: Type 2 diabetes (T2D) is a multifactorial, heritable syndrome characterized by dysregulated glucose homeostasis that results from impaired insulin secretion and insulin resistance. Genetic association studies have successfully identified hundreds of T2D risk loci implicating many genes in disease pathogenesis. In this review, we provide an overview of the recent T2D genetic studies from the past 3 years with particular focus on the effects of sample size and ancestral diversity on genetic discovery as well as discuss recent work on the use and limitations of genetic risk scores (GRS) for T2D risk prediction.Recent findings: Recent large-scale, multi-ancestry genetic studies of T2D have identified over 500 novel risk loci. The genetic variants (i.e., single nucleotide polymorphisms (SNPs)) marking these novel loci in general have smaller effect sizes than previously discovered loci. Inclusion of samples from diverse ancestral backgrounds shows a few ancestry specific loci marked by common variants, but overall, the majority of loci discovered are common across ancestries. Inclusion of common variant GRS, even with hundreds of loci, does not substantially increase T2D risk prediction over standard clinical risk factors such as age and family history. Common variant association studies of T2D have now identified over 700 T2D risk loci, half of which have been discovered in the past 3 years. These recent studies demonstrate that inclusion of ancestrally diverse samples can enhance locus discovery and improve accuracy of GRS for T2D risk prediction. GRS based on common variants, however, only minimally enhances risk prediction over standard clinical risk factors.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"22 5","pages":"227-235"},"PeriodicalIF":4.2,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10775524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 22

Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists. 矿盐皮质激素受体拮抗剂治疗糖尿病肾病:在SGLT2抑制剂和GLP-1受体激动剂时代的应用

IF 4.2 2区医学

Current Diabetes Reports Pub Date : 2022-05-01 DOI: 10.1007/s11892-022-01461-4

Scott Cohen, Hillel Sternlicht, George L Bakris

{"title":"Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists.","authors":"Scott Cohen, Hillel Sternlicht, George L Bakris","doi":"10.1007/s11892-022-01461-4","DOIUrl":"https://doi.org/10.1007/s11892-022-01461-4","url":null,"abstract":"Purpose of review: This review focuses on new clinical data involving a novel class of drugs, nonsteroidal mineralocorticoid receptor antagonists (NS-MRAs), specifically, finerenone and its effects on cardiovascular and diabetic kidney disease outcomes.Recent findings: NS-MRAs are a novel class of agents for treating diabetic kidney disease (DKD). While they are chemically and pharmacologically distinct from steroidal MRAs (spironolactone, eplerenone), they effectively inhibit the MR receptor differently. Inhibition of MR receptor activation reduces inflammatory and profibrotic pathways involving the cardiorenal/vascular systems. Small diabetic kidney disease (DKD) clinical studies demonstrate that steroidal MRAs reduce albuminuria relative to placebo, although hyperkalemia is a major adverse event that has precluded large outcome trials. The NS-MRA, finerenone, demonstrated slowed progression of DKD and reduction of cardiovascular death primarily driven by reduced heart failure incidence in two separate randomized controlled clinical trials (FIDELIO and FIGARO). Use of NS-MRAs, therefore, provides a third \"pillar of therapy\" to reduce cardiorenal events added to blockers of the renin-angiotensin system and SGLT2 inhibitors. If the pending outcome trial, FLOW, is positive, potentially, GLP1-RAs may also be part of this \"pillar\" structure.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"22 5","pages":"213-218"},"PeriodicalIF":4.2,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10832840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Applying Behavioral Economics Theories to Interventions for Persons with Diabetes. 将行为经济学理论应用于对糖尿病患者的干预。

IF 5.2 2区医学

Current Diabetes Reports Pub Date : 2022-05-01 Epub Date: 2022-03-10 DOI: 10.1007/s11892-022-01460-5

Susana R Patton, Christopher C Cushing, Amy Hughes Lansing

{"title":"Applying Behavioral Economics Theories to Interventions for Persons with Diabetes.","authors":"Susana R Patton, Christopher C Cushing, Amy Hughes Lansing","doi":"10.1007/s11892-022-01460-5","DOIUrl":"10.1007/s11892-022-01460-5","url":null,"abstract":"Purpose of review: To introduce behavioral economics (BE), provide a description of how recent prevention and treatment interventions in persons with diabetes have incorporated BE in their intervention strategies, and discuss how BE could be used to inform new treatments for the clinical setting or research.Recent findings: In most of the trials described, researchers incorporated BE into their design in the form of incentives, which can align with present bias, optimism bias, and loss aversion. With only two exceptions, these trials reported preliminary support for using incentives to promote lifestyle modifications and diabetes-related tasks. Additionally, two trials reported promising results for behavior change strategies informed by default bias, while three trials reported promising results for behavior change strategies informed by social norms. Recent trials incorporating BE in prevention and treatment interventions for persons with diabetes generally report promising results, though gaps exist for research and clinical deployment.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"22 5","pages":"219-226"},"PeriodicalIF":5.2,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951181/pdf/nihms-1868970.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9407877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0